AbbVie says Rinvoq shines again as maintenance therapy for ulcerative colitis — but safety concerns still loom over JAK class

Even as Rinvoq gets swept up in the FDA’s look into the safety of JAK inhibitors as a class, AbbVie is continuing to roll out data that it says point to new approvals down the road.

The drug has hit the primary and all secondary endpoints in a one-year study designed to test whether it works as a maintenance treatment for moderate to severe cases of ulcerative colitis, AbbVie said. On the key metrics of safety, the drugmaker reported no new concerns.